| 产品描述: | EGFR T790M/L858R-IN-2 is a potent and selective EGFRT790M/L858R inhibitor with IC50 values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. EGFR T790M/L858R-IN-2 decreases the expression of p-EGFR, P-AKT, P-ERK1/2. EGFR T790M/L858R-IN-2 induces Apoptosis and cell cycle arrest in the G1 phase. EGFR T790M/L858R-IN-2 shows anti-cancer activity. |
| 靶点: |
EGFRL858R/T790M:3.5 nM (IC50); EGFR (WT):1290 nM (IC50); EGFRT790M:6.7 nM (IC50); EGFRL858R:2.1 nM (IC50) |
| 体外研究: |
EGFR T790M/L858R-IN-2 (5、10、20 mg/kg;i.p.;每天) 以剂量依赖性方式抑制肿瘤生长。 |
| 体内研究: |
EGFR T790M/L858R-IN-2 (compound 28f) (0.1, 1, 10 µM; 4 h)以剂量依赖性方式降低 H1975、HCC827 细胞中 p-EGFR、P-AKT、P-ERK1/2 的表达. EGFR T790M/L858R-IN-2 (0.1、1、10 µM;48 小时) 在 H1975、HCC827 细胞中诱导细胞凋亡和细胞周期停滞于 G1 期。 EGFR T790M/L858R-IN-2 (0.1、1、10 µM;14 天) 以剂量依赖性方式抑制集落形成和细胞迁移。 |
| 参考文献: |
1. Pei J, et al. Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer. J Med Chem. 2023 Apr 27;66(8):5719-5752. |
| 保存条件: |
-80°C 6个月;-20°C 1个月 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.01 ml |
10.049 ml |
20.098 ml |
| 5 mM |
0.402 ml |
2.01 ml |
4.02 ml |
| 10 mM |
0.201 ml |
1.005 ml |
2.01 ml |
| 50 mM |
0.04 ml |
0.201 ml |
0.402 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |